Page last updated: 2024-08-25

oxazolidin-2-one and Uterine Neoplasms

oxazolidin-2-one has been researched along with Uterine Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Castellucci, C; Ciarmela, P; Ciavattini, A; Greco, S; Islam, MS; Janjusevic, M; Petraglia, F; Toti, P	1

Other Studies

1 other study(ies) available for oxazolidin-2-one and Uterine Neoplasms

Article	Year
Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells. Fertility and sterility, 2016, Volume: 106, Issue:6 Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Female; Glycogen Synthase Kinase 3 beta; Humans; Leiomyoma; Myocytes, Smooth Muscle; Myometrium; Oxazolidinones; Phosphatidylethanolamine Binding Protein; Phosphorylation; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms	2016

Article

Year

Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.

Fertility and sterility, 2016, Volume: 106, Issue:6

Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Female; Glycogen Synthase Kinase 3 beta; Humans; Leiomyoma; Myocytes, Smooth Muscle; Myometrium; Oxazolidinones; Phosphatidylethanolamine Binding Protein; Phosphorylation; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms

2016